Olanzapine for Cancer Related Anorexia-cachexia Syndrome

Summary

Cancer anorexia-cachexia syndrome is one of the common conditions in cancer patients. Olanzapine has been demonstrated to reduce chemotherapy-induced anorexia. However, there is scarce information regarding olanzapine as a treatment of cancer anorexia among patients who does not receive chemotherapy. Therefore, this randomized controlled trial aims to evaluate the efficacy of olanzapine to lessen cancer cachexia-anorexia syndrome.

Eligibility

Inclusion Criteria:

* pathologically or cytologically metastatic or locally advanced cancer
* anorexia and \>=5% weight loss during the past 6 months or anorexia with numerical scale of anorexia \>=5
* ECOG performance status 0-3
* able to complete questionaire and able to swallow pills

Exclusion Criteria:

* receiving chemotherapy or anti-cancer systemic therapy
* life expectancy longer than 1 month
* received radiotherapy at head/neck or thoracic or upper abdomen in the past 2 weeks
* surgery within 4 weeks
* pregnancy
* serum bilirubin \> 2 mg/dl or serum Cr \> 2 mg/dl
* current use of olanzapine or other antipsychotic drug
* known cardiac arrhythmia, uncontrolled brain metastasis, history of seizure or acute coronary event in the past 6 months

Conditions4

Browse More Trials